Cleerly LABS vs AVIEW Lung Nodule CAD
AI Verdict
Choose Cleerly LABS if…
Choose Cleerly LABS if your primary objective is a detailed, AI-powered quantitative analysis of coronary CT angiography (CCTA) to precisely characterize atherosclerosis and stenosis. This tool is ideal for clinicians focused on personalized heart disease management, needing to understand plaque volume and type, track disease progression over time, and assess individual risk for heart attacks.
View Cleerly LABS →Choose AVIEW Lung Nodule CAD if…
Choose AVIEW Lung Nodule CAD if your focus is on comprehensive AI-assisted screening and follow-up for pulmonary nodules on chest CT scans, particularly for lung cancer detection and management. This solution is also highly beneficial for simultaneously assessing other critical thoracic conditions like emphysema and coronary artery calcification, providing a holistic view of lung and cardiovascular health from a single scan.
View AVIEW Lung Nodule CAD →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cleerly LABS | AVIEW Lung Nodule CAD |
|---|---|---|
| Pricing | Varies | Unknown |
| Deployment | Cloud, On-premise | On-premises and cloud environment |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Cleerly LABSCleerly LABS is explicitly described as a 'web-based software' and 'web-based application', suggesting a focus on accessibility and a potentially intuitive user interface. While AVIEW Lung Nodule CAD offers flexible deployment options, it does not provide specific details about its user experience or interface, making it harder to assess its direct usability for clinicians.
Clinical Value
AVIEW Lung Nodule CADAVIEW Lung Nodule CAD offers comprehensive screening for lung cancer, COPD, and coronary artery calcification (the 'Big 3') from a single chest CT scan, providing broad clinical utility across multiple critical conditions. Cleerly LABS provides deep, personalized analysis of coronary atherosclerosis, which is highly valuable, but AVIEW's ability to simultaneously address three major health concerns offers a wider immediate impact for population health screening.
Pricing & Value
Cleerly LABSCleerly LABS provides transparent pricing details, including a retail price and a discounted offer, allowing potential users to understand the financial commitment upfront. In contrast, AVIEW Lung Nodule CAD's pricing is not publicly disclosed, making it difficult for customers to assess its value proposition without direct contact.
Enterprise Readiness
Cleerly LABSCleerly LABS explicitly states it has a Business Associate Agreement (BAA) and offers integration with PACS, RIS, and EHR systems via its Cleerly Proxy, which are crucial for seamless enterprise deployment and data management in healthcare. While AVIEW Lung Nodule CAD offers flexible deployment options, it does not explicitly detail its integration capabilities with existing hospital IT infrastructure or BAA status in the provided information.
Innovation
Cleerly LABSCleerly LABS demonstrates significant innovation by focusing on comprehensive coronary plaque characterization (volume, type) and tracking disease progression, moving beyond traditional stenosis assessment for personalized heart disease management. While AVIEW's 'Big 3' simultaneous analysis is also innovative for maximizing CT scan utility, Cleerly's deeper dive into the pathophysiology of atherosclerosis represents a more novel approach in its specific cardiology domain.
Support & Docs
TieNeither the provided structured facts nor general web searches revealed specific comparative details regarding the depth, availability, or quality of support and documentation for either Cleerly LABS or AVIEW Lung Nodule CAD. Both companies appear to offer standard customer support and resources, making it impossible to distinguish a winner in this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cleerly LABS | AVIEW Lung Nodule CAD |
|---|---|---|
| Primary Application/Focus | AI-powered, FDA-cleared web-based software for comprehensive analysis of coronary CT angiography (CCTA) to detect, quantify, and characterize atherosclerosis and stenosis, aiding in personalized heart disease management. | AI-powered software that assists radiologists in detecting and analyzing pulmonary nodules on chest CT scans, and offers comprehensive screening for lung cancer, COPD, and coronary artery calcification. |
| Company | Cleerly | Coreline Soft Co. |
| Target Specialties | Cardiology, Radiology | Cardiology, Pulmonology, Radiology |
| Core AI Analysis | AI-powered CCTA image analysis, Comprehensive coronary plaque assessment (volume, type), Stenosis detection and quantification. | AI-based pulmonary nodule detection (3-20 mm) on CT scans, Nodule classification (solid, part-solid, non-solid), 3D nodule size and volume quantification. |
| Additional Screening Capabilities | Ischemia detection (with Cleerly ISCHEMIA module). | Simultaneous analysis of lung nodules, emphysema, and coronary artery calcification (Big 3), Quantitative emphysema analysis (e.g., Low Attenuation Area - LAA, emphysema index), Coronary Artery Calcification (CAC) scoring (Agatston, volume, mass scores). |
| Reporting/Visualization Features | 3D visualization of coronary arteries, Personalized heart disease risk assessment, Tracking disease progression over time. | Automatic report generation based on Lung-RADS classification, Nodule matching and volume doubling time (VDT) calculation for follow-up comparisons. |
Videos
Demos, reviews, and walkthroughs featuring Cleerly LABS and AVIEW Lung Nodule CAD.
Frequently Asked Questions
More Comparisons
More matchups featuring Cleerly LABS or AVIEW Lung Nodule CAD
Backers
Who funded each tool's parent company.